Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme glucocerebrosidase (GCase), encoded by the [GBA1](/genes/gba1) gene on chromosome 1q21. This enzyme deficiency leads to accumulation of glucosylceramide (GL-1, also known as glucosylsphingosine or lyso-GL1) in macrophages (Gaucher cells) throughout the body, including the brain in certain subtypes. [@grabowski2023] Gaucher disease represents the most common lysosomal storage disorder, with an estimated prevalence of 1 in 40,000 to 1 in 60,000 in the general population, though higher frequencies are observed in Ashkenazi Jewish populations (approximately 1 in 850). [@zimran2021]
The clinical spectrum of Gaucher disease ranges from asymptomatic carriers to severe, life-threatening multisystem disease. The phenotypic variability is largely driven by the nature of the underlying GBA1 mutation and the resulting residual glucocerebrosidase enzyme activity. [@hruska2022]
Gaucher disease exhibits marked population-specific prevalence variations. Among Ashkenazi Jews, the carrier frequency is approximately 1 in 12-15, leading to a predicted disease incidence of approximately 1 in 850 live births. [@zimran2021] This high carrier frequency is attributed to a founder effect, with four common mutations (N370S, L444P, 84insG, IVS2+1) accounting for over 90% of disease alleles in this population.
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme glucocerebrosidase (GCase), encoded by the [GBA1](/genes/gba1) gene on chromosome 1q21. This enzyme deficiency leads to accumulation of glucosylceramide (GL-1, also known as glucosylsphingosine or lyso-GL1) in macrophages (Gaucher cells) throughout the body, including the brain in certain subtypes. [@grabowski2023] Gaucher disease represents the most common lysosomal storage disorder, with an estimated prevalence of 1 in 40,000 to 1 in 60,000 in the general population, though higher frequencies are observed in Ashkenazi Jewish populations (approximately 1 in 850). [@zimran2021]
The clinical spectrum of Gaucher disease ranges from asymptomatic carriers to severe, life-threatening multisystem disease. The phenotypic variability is largely driven by the nature of the underlying GBA1 mutation and the resulting residual glucocerebrosidase enzyme activity. [@hruska2022]
Gaucher disease exhibits marked population-specific prevalence variations. Among Ashkenazi Jews, the carrier frequency is approximately 1 in 12-15, leading to a predicted disease incidence of approximately 1 in 850 live births. [@zimran2021] This high carrier frequency is attributed to a founder effect, with four common mutations (N370S, L444P, 84insG, IVS2+1) accounting for over 90% of disease alleles in this population.
Globally, the estimated incidence ranges from 0.5 to 2.5 per 100,000 live births, depending on the population studied. Type 1 Gaucher disease is the most common form, representing approximately 95% of cases in Western populations, while neuronopathic forms (Type 2 and Type 3) are more prevalent in other regions. [@grabowski2023]
The GBA1 gene (OMIM *606463) spans approximately 7.6 kb and contains 11 exons. Over 400 disease-causing mutations have been identified, including point mutations, insertions, deletions, and splice site variants. The most common pathogenic variants include: [@hruska2022]
Glucocerebrosidase (GCase, EC 3.2.1.45) is a 497-amino acid glycoprotein that functions as a homodimer in the lysosome. The enzyme catalyzes the hydrolysis of glucosylceramide (GL-1) to ceramide and glucose within the lysosomal compartment. [@schmitz2022] Proper enzyme function requires correct folding in the endoplasmic reticulum, trafficking through the Golgi apparatus, and delivery to lysosomes via the mannose-6-phosphate receptor pathway.
The crystal structure of GCase reveals a TIM-barrel fold with an active site containing two catalytic glutamate residues (Glu235 and Glu340). Mutations can affect enzyme function through multiple mechanisms: [@schmitz2022]
The accumulation of glucosylceramide in macrophages leads to the formation of characteristic Gaucher cells - lipid-engorged macrophages with a "wrinkled tissue paper" appearance on light microscopy. These cells measure 20-100 μm in diameter and contain abundant cytoplasmic inclusions that stain positively with periodic acid-Schiff (PAS) due to the glycolipid content. [@bennett2021]
Gaucher cells accumulate in bone marrow, liver, spleen, and other tissues, where they contribute to disease pathogenesis through multiple mechanisms:
Beyond glucosylceramide (GL-1), patients with Gaucher disease also accumulate elevated levels of glucosylsphingosine (Lyso-GL1), a deacylated derivative. Lyso-GL1 is considered a more sensitive biomarker of disease severity than GL-1, as it more directly reflects intracellular enzyme deficiency. [@rozmahel2023] Lyso-GL1 is also elevated in the cerebrospinal fluid of patients with neuronopathic disease and is being investigated as a biomarker for therapeutic response.
| Type | CNS Involvement | Key Features | Life Expectancy |
|------|-----------------|--------------|-----------------|
| Type 1 | None | Visceral disease, bone crisis | Normal with treatment |
| Type 2 | Acute neuronopathic | Rapid neurodegeneration, death by 2 years | <2 years |
| Type 3 | Chronic neuronopathic | Subacute neurodegeneration | Variable, decades |
Type 1 Gaucher disease is characterized by the absence of primary central nervous system involvement. Clinical manifestations typically present in childhood or adolescence, though diagnosis may be delayed until adulthood. [@grabowski2023]
Hepatosplenomegaly: Enlargement of the liver and spleen is present in the majority of patients. Splenomegaly can be massive, with spleen volumes exceeding 15 times normal. Hypersplenism contributes to cytopenias. [@grabowski2023]
Bone Disease: Bone manifestations include: [@mistry2021]
Other Manifestations: Pulmonary involvement (interstitial lung disease), increased risk of certain malignancies (multiple myeloma, hepatocellular carcinoma), and immune dysfunction. [@grabowski2023]
Type 2 (acute neuronopathic) Gaucher disease is the most severe form, characterized by rapid neurodegenerative decline in infancy. [@vom2022] Affected infants appear normal at birth but develop symptoms within the first 6 months:
Type 3 (chronic neuronopathic) Gaucher disease presents a heterogeneous phenotype with variable rates of neurological progression. Three subtypes are recognized: [@gurses2023]
The definitive diagnosis of Gaucher disease relies on measurement of glucocerebrosidase enzyme activity in peripheral blood leukocytes or dried blood spots. [@alonso2022] Activities below 10-15% of normal are diagnostic, though carrier detection is less reliable due to overlap with normal ranges.
GBA1 sequencing identifies pathogenic variants and confirms diagnosis. Comprehensive testing should include: [@alonso2022]
Recombinant glucocerebrosidase preparations effectively treat Type 1 and non-neuronopathic Type 3 disease by reducing substrate accumulation in visceral organs. [@weinreb2023]
| Drug | Dose | Administration |
|------|------|----------------|
| Imiglucerase (Cerezyme®) | 60 U/kg every 2 weeks | IV infusion |
| Velaglucerase alfa (VPRIV®) | 60 U/kg every 2 weeks | IV infusion |
| Taliglucerase alfa (Elelyso®) | 60 U/kg every 2 weeks | IV infusion |
ERT achieves: [@weinreb2023]
Oral small molecule therapies reduce glucosylceramide production through inhibition of glucosylceramide synthase (GCS). [@peterschmitt2022]
| Drug | Indication | Mechanism |
|------|------------|-----------|
| Eliglustat tartrate (Cerdelga®) | Type 1 (adults) | GCS inhibitor |
| Miglustat (Zavesca®) | Type 1, Type 3 | GCS inhibitor |
SRT is contraindicated in patients with severe cardiac or renal disease due to drug interactions. Miglustat is associated with gastrointestinal side effects. [@peterschmitt2022]
Pharmacological chaperones bind to mutant GCase, promoting proper folding and lysosomal trafficking. [@schumann2021]
AAV-vector based gene therapy approaches are in preclinical and early clinical development. These approaches aim to deliver functional GBA1 to patient tissues, potentially providing long-term correction. [@klein2023]
Heterozygous GBA1 mutations are the most significant genetic risk factor for Parkinson's disease, increasing risk 5-6 fold. [@sidransky2022] The relationship involves bidirectional links between glucocerebrosidase and [alpha-synuclein](/proteins/alpha-synuclein) metabolism: [@sidransky2022][@mazzulli2021]
Multiple clinical trials are investigating new treatments for Gaucher disease and related conditions: [@clinicaltrialsgov]
Key research areas include: [@klein2023]